Low-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors

Neurology

Volumn 46, Issue 4, 1996, Pages 999-1003

  Blum, A S ^a,c   Dal Pan, G J ^a   Feinberg, J ^a   Raines, C ^a   Mayjo, K ^a   Cornblath, D R ^a   McArthur, J C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY NEUROPATHY;

EID: 9244235985     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.4.999     Document Type: Article

References (23)

1. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988;45:945-948.
2. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex Neurology 1988;38:794-796.
3. Griffin JW, Crawford TO, Glass JD, Price DL, Cornblath DR, McArthur JC. Sensory neuropathy in AIDS: I. Neuropathology. Brain 1996 (in press).
4. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911-1915.
5. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2′3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81.
6. Merigan TC, Skowron G, Bozzette SA, et al., The DDC Study Group of the AIDS Clinical Trials Group. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med 1989;110:189-195.
7. Dubinsky RM, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 1989;12:856-860.
8. Merigan TC, Skowron G, the ddC Study Group. Safety and tolerance of dideoxycytidine as a single agent. Am J Med 1990;88(suppl 5B):11S-15S.
9. Meng T, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116:13-20.
10. Berger AR, Arezzo JC, Schaumburg HH, et al. 2′,3′-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients Neurology 1993;43:358-362.
11. Abrams DI, Goldman AI, Launer C, et al., the Terry Beim Community Programs for Clinical Research on AIDS. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994;330:657-662.
12. Arezzo JC, Schaumburg HH, Petersen CA. Rapid screening for peripheral neuropathy: a field study with the Optacon. Neurology 1983;33:626-629.
13. Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics 1978; 34:469-474.
14. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955;19:251-253.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Fischl MA, Stanley K, Collier AC, et al., NIAID ACTG. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122:24-32.
17. Hogan-Dann CM, Fellmeth WG, McGuire SA, Kiley VA. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984;252:2862-2863.
18. Dubinsky RM, Dalakas M, Yarchoan R, Broder S. Follow-up of neuropathy from 2′3′-dideoxycytidine. Lancet 1988;1:832.
19. Arezzo JC, Schaumburg HH, Schroeder C, Litwak M. Dideoxycytidine (ddC) neuropathy: an animal model in the cynomolgus monkey. Neurology 1990;40(suppl 1):428.
20. Anderson TD, Davidovich A, Arceo R, Brosnan C, Arezzo J, Schaumburg H. Peripheral neuropathy induced by 2′,3′-dideoxycytidine. Lab Invest 1991;66:63-74.
21. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989;321:726-738.
22. Starnes MC, Cheng YC. Cellular metabolism of 2′3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem 1987;262:988-991.
23. Chen C, Cheng Y. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′3′-dideoxycytidine. J Biol Chem 1992;267:2856-2859.